Eli Lilly and Company $LLY Shares Purchased by Platform Technology Partners

Posted by George Bondi on Nov 6th, 2026

Eli Lilly and Company logo Platform Technology Partners increased its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 13.9% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 3,678 shares of the company’s stock after acquiring an additional 448 shares during the period. Platform Technology Partners’ holdings in Eli Lilly and Company were worth $4,256,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Quest 10 Wealth Builders Inc. boosted its position in shares of Eli Lilly and Company by 27.5% during the third quarter. Quest 10 Wealth Builders Inc. now owns 139 shares of the company’s stock worth $161,000 after acquiring an additional 30 shares during the last quarter. Commonwealth Equity Services LLC grew its stake in Eli Lilly and Company by 17.4% during the third quarter. Commonwealth Equity Services LLC now owns 404,753 shares of the company’s stock valued at $468,332,000 after acquiring an additional 59,905 shares in the last quarter. Wealth Dimensions Group Ltd. increased its holdings in Eli Lilly and Company by 1.1% in the 3rd quarter. Wealth Dimensions Group Ltd. now owns 3,667 shares of the company’s stock valued at $4,243,000 after acquiring an additional 40 shares during the last quarter. Collaborative Fund Advisors LLC increased its holdings in Eli Lilly and Company by 25.1% in the 3rd quarter. Collaborative Fund Advisors LLC now owns 1,537 shares of the company’s stock valued at $1,778,000 after acquiring an additional 308 shares during the last quarter. Finally, Pathway Financial Advisers LLC increased its holdings in Eli Lilly and Company by 2.8% in the 3rd quarter. Pathway Financial Advisers LLC now owns 2,972 shares of the company’s stock valued at $3,439,000 after acquiring an additional 80 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the topic of several research analyst reports. Citigroup boosted their price target on shares of Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Truist Financial restated a “buy” rating and set a $1,612.00 price objective (up from $1,376.00) on shares of Eli Lilly and Company in a research report on Friday, October 30th. Guggenheim lifted their target price on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a report on Friday, September 18th. Scotiabank boosted their target price on Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the stock a “sector outperform” rating in a research report on Friday, October 30th. Finally, JPMorgan Chase & Co. increased their price target on Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $1,404.14.

View Our Latest Analysis on Eli Lilly and Company

Insider Activity

In related news, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares in the company, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. This represents a 56.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 13,500 shares of company stock worth $17,020,770. 0.14% of the stock is currently owned by corporate insiders.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Lilly reported encouraging Phase 3 results for investigational retatrutide in people with knee osteoarthritis and obesity, including substantial weight and knee-pain reductions. New data also showed benefits from combining Zepbound with Taltz in adults with psoriatic arthritis and obesity, supporting the potential of Lilly’s obesity franchise across additional conditions. Lilly ACR Convergence data
Positive Sentiment: Recent earnings momentum remains a support: Lilly beat Q3 estimates and raised its outlook, reinforcing expectations for strong demand for its medicines. Commentary also presents LLY as a potential defensive holding amid the technology selloff, which could attract investors seeking growth outside tech. LLY as a potential safe haven
Negative Sentiment: Investors are also watching growing price competition in the GLP-1 market. Lower realized prices could temper the revenue and profit growth investors expect from Lilly’s highly valued obesity-drug business. GLP-1 price competition

Eli Lilly and Company Trading Down 3.5%

Shares of LLY opened at $1,368.85 on Friday. The stock has a market capitalization of $1.29 trillion, a PE ratio of 44.43, a P/E/G ratio of 1.77 and a beta of 0.40. The company’s fifty day moving average is $1,211.30 and its 200 day moving average is $1,099.50. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. Eli Lilly and Company has a fifty-two week low of $850.51 and a fifty-two week high of $1,453.00.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. During the same quarter last year, the business earned $7.02 earnings per share. Eli Lilly and Company’s quarterly revenue was up 38.6% compared to the same quarter last year. Sell-side analysts expect that Eli Lilly and Company will post 35.70 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company’s payout ratio is 22.46%.

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.